Scribe Therapeutics Inc. Common Stock
SCTX| Date | Action | ETF | Shares | Close | Est. total |
|---|---|---|---|---|---|
| 26.08.18 | BUY | ARKG | 5,614 | $27.11 | $152.2K |
| 26.08.17 | BUY | ARKG | 15,823 | $21.19 | $335.3K |
| 26.07.24 | BUY | ARKG | 361,253 | $22.00 | $7.9M |
Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
Analyst Consensus
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Price Information
Trading Volume
Valuation
Financials
Profitability
Dividend
Technical
Scribe Therapeutics is a biotechnology company that develops CRISPR-based genetic medicines to treat the root causes of diseases, focusing on cardiometabolic conditions. Its main programs include STX-1150 for epigenetic silencing of the PCSK9 gene, STX-1200 for gene editing to lower Lp(a), and STX-1400 to target the APOC3 gene. The company uses platforms like ELXR and XE to enable precise gene editing and silencing, and it operates as a clinical-stage firm based in Alameda, California.
AI-generated summary. Not investment advice.
Related ARK stocks
Explore companies with similar themes or neighboring ARK trading activity.